Cisatracurium Besilate Injection

Effects and efficacy:
General anesthesia assistance. Surgery and other operations, such as endotracheal intubation. Intensive care treatment.
Dosage and administration:
Intravenous single injection administration Adult dose endotracheal intubation: The recommended dose of this product for adult intubation is 0.15 mg per kilogram of body weight or as directed by a doctor. Children aged 2 to 12 years The recommended dose of the first dose of cisatracurium besylate for children aged 2 to 12 years is 0.1 mg/kg body weight and is administered within 5 to 10 seconds. The recommended dose for intravenous drip administration for adults and children aged 2 to 12 years is first infused at a rate of 3 μg/kg/min. Once a stable state is reached, most patients only need a continuous infusion of 1 to 2 μg/kg/min to maintain the blocking effect.
Adverse reactions:
This product is highly safe, has no histamine release effect, and has no cardiovascular adverse reactions. There are rare reports of epilepsy in ICU patients using atracurium or other drugs. These patients usually have one or more predisposing factors that are prone to epilepsy (such as brain trauma, cerebral hypoxia, cerebral edema, viral encephalitis, uremia).
Contraindications:
Contraindicated if allergic to this product; contraindicated during pregnancy